Conditions are getting a bit more challenging for the drugmaker.

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 830% — a ...

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

But in the last few years, Eli Lilly was a great investment — mostly due to the success of Mounjaro and Zepbound. Nevertheless, the stock seems expensive — also when compared to Novo Nordisk ...

Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.

Lilly announced its third-quarter results on Wednesday. Investors didn't like what they heard. The big pharma stock initially plunged close to 15% after the market opened on Thursday before ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company ...